Observational Study of Muscle Invasive Urothelial Carcinoma Participants Treated With Adjuvant Nivolumab in France
← catalyst calendarSponsored by Bristol-Myers Squibb (industry) · BMY — their whole pipeline →.
Phase
—
Status
Terminated
Study type
Observational
Enrollment
176actual
Sites
1
Country
France
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Why the sponsor stopped it
Business objectives have changed
As filed on the registry record, in the sponsor's own words.
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-07-30 | actual | When the study began enrolling |
| Primary completion | 2025-04-04 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-04-04 | actual | The whole study's end, after follow-up |
| First posted | 2024-05-20 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-06-05 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Urothelial Carcinoma
Intervention
- Drug: nivolumab
Primary outcome
what the primary-completion date above is the date OFDisease-free survival (DFS) of participants
measured At months 3, 6, 9, 12, 18, 24, 30, 26, 48 and 60
Permalink · BMY's whole pipeline · Catalyst calendar · Every registered study · What changed